For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 24,769 | |||
| General and administrative | 13,340 | |||
| Total operating expenses | 38,109 | |||
| Loss from operations | -38,109 | |||
| Interest income | 2,934 | |||
| Other income | 1 | |||
| Net loss attributable to common stockholders | -35,174 | |||
| Unrealized gain (loss) on investments | 26 | |||
| Comprehensive loss | -35,148 | |||
| Basic EPS | -1.16 | |||
| Diluted EPS | -1.16 | |||
| Basic Average Shares | 30,215,747 | |||
| Diluted Average Shares | 30,215,747 | |||
AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. (ANTX)